{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:02Z","timestamp":1787021042117,"version":"build-2736575974"},"reference-count":17,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0261-2","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T07:56:49Z","timestamp":1499759809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma"],"prefix":"10.1136","volume":"5","author":[{"given":"Lea","family":"Bottlaender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Breton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"de Laforcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Dijoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"261_CR1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"261_CR2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, et al. Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1:433\u201340.","journal-title":"JAMA Oncol"},{"key":"261_CR3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122\u201333.","journal-title":"N Engl J Med"},{"key":"261_CR4","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","volume":"22","author":"B Thajudeen","year":"2015","unstructured":"Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am J Ther. 2015;22:e84\u20137.","journal-title":"Am J Ther"},{"key":"261_CR5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","volume":"32","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, et al. Kidney injuries related to ipilimumab. Investig New Drugs. 2014;32:769\u201373.","journal-title":"Investig New Drugs"},{"key":"261_CR6","first-page":"2045","volume":"8","author":"E Mashima","year":"2015","unstructured":"Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, et al. Nivolumab in the treatment of malignant melanoma: review of the literature. OncoTargets Ther. 2015;8:2045\u201351.","journal-title":"OncoTargets Ther"},{"key":"261_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5414\/CN10838","volume":"82","author":"R Raghavan","year":"2014","unstructured":"Raghavan R, Eknoyan G. Acute interstitial nephritis - a reappraisal and update. Clin Nephrol. 2014;82:149\u201362.","journal-title":"Clin Nephrol"},{"key":"261_CR8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5414\/CN108254","volume":"84","author":"L Zand","year":"2015","unstructured":"Zand L, Monaghan M, Griffin BR, Wagner SJ, Criaci IM, Kamal A, et al. The role of type I hypersensitivity reaction and IgE-mediated mast cell activation in acute interstitial nephritis. Clin Nephrol. 2015;84:138\u201344.","journal-title":"Clin Nephrol"},{"key":"261_CR9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1523-1755.2001.060002804.x","volume":"60","author":"J Rossert","year":"2001","unstructured":"Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60:804\u201317.","journal-title":"Kidney Int"},{"key":"261_CR10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"N Murakami","year":"2016","unstructured":"Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9:411\u20137.","journal-title":"Clin Kidney J"},{"key":"261_CR11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45:160\u20139.","journal-title":"Am J Nephrol"},{"key":"261_CR12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ki.2015.30","volume":"87","author":"MA Perazella","year":"2015","unstructured":"Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015;87:909\u201317.","journal-title":"Kidney Int"},{"key":"261_CR13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","volume":"66","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66:857\u201368.","journal-title":"Am J Kidney Dis"},{"key":"261_CR14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","volume":"23","author":"J Sunshine","year":"2015","unstructured":"Sunshine J, Taube JM. PD-1\/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32\u20138.","journal-title":"Curr Opin Pharmacol"},{"key":"261_CR15","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.124","volume":"112","author":"B Homet Moreno","year":"2015","unstructured":"Homet Moreno B, Ribas A. Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers. Br J Cancer. 2015;112:1421\u20137.","journal-title":"Br J Cancer"},{"key":"261_CR16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"37","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin Ther. 2015;37:764\u201382.","journal-title":"Clin Ther"},{"key":"261_CR17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0261-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:42:43Z","timestamp":1601041363000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0261-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0261-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]},"article-number":"57"}}